Journal article
TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial
Abstract
BACKGROUND: The purpose of this randomised double-blind double-dummy placebo-controlled trial was to investigate whether etanercept, a tumour necrosis factor α (TNFα) antagonist, would provide more effective anti-inflammatory treatment for acute exacerbations of chronic obstructive pulmonary disease (COPD) than prednisone.
METHODS: We enrolled 81 patients with acute exacerbations of COPD and randomly assigned them to treatment with either 40 mg …
Authors
Aaron SD; Vandemheen KL; Maltais F; Field SK; Sin DD; Bourbeau J; Marciniuk DD; FitzGerald JM; Nair P; Mallick R
Journal
Thorax, Vol. 68, No. 2,
Publisher
BMJ
Publication Date
2 2013
DOI
10.1136/thoraxjnl-2012-202432
ISSN
0040-6376
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAnti-Inflammatory Agents, Non-SteroidalDisease ProgressionDouble-Blind MethodEtanerceptFemaleForced Expiratory VolumeGlucocorticoidsHumansImmunoglobulin GLevofloxacinMaleMiddle AgedOfloxacinPrednisonePulmonary Disease, Chronic ObstructiveReceptors, Tumor Necrosis FactorTreatment OutcomeTumor Necrosis Factor-alpha